Hospital de Santa Maria-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2024

  1. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029

2022

  1. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  2. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease

    Gut, Vol. 71, Núm. 9, pp. 1856-1866

  3. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

2021

  1. Pressure injury prediction models for critically-ill patients should consider both the case-mix and local factors

    Intensive and Critical Care Nursing

2020

  1. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Blood Cancer Journal, Vol. 10, Núm. 10

  2. Major bleeding predictors in patients with left atrial appendage closure: The iberian registry ii

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-11

  3. Protein succination as a potential surrogate biomarker of airway obstruction. The ilervas project

    Respiratory Medicine, Vol. 172

2019

  1. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas

    Nature Communications, Vol. 10, Núm. 1

  2. Long-term Event Reduction After Left Atrial Appendage Closure. Results of the Iberian Registry II

    Revista Espanola de Cardiologia, Vol. 72, Núm. 6, pp. 449-455

2018

  1. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

  2. Erratum to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC‑GLOSSARI): a multicenter, multinational, 14-day inception cohort study (Intensive Care Medicine, (2016), 42, 5, (953), 10.1007/s00134-016-4317-4)

    Intensive Care Medicine

  3. Heterogeneity within the PF-EPN-B ependymoma subgroup

    Acta Neuropathologica, Vol. 136, Núm. 2, pp. 227-237

2017

  1. Intertumoral Heterogeneity within Medulloblastoma Subgroups

    Cancer Cell, Vol. 31, Núm. 6, pp. 737-754.e6

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis

    The Lancet Oncology, Vol. 17, Núm. 4, pp. 484-495

  3. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

2015

  1. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels

    BMC Infectious Diseases, Vol. 14, Núm. 1